These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 27999020)

  • 1. Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models.
    Robertson GT; Scherman MS; Bruhn DF; Liu J; Hastings C; McNeil MR; Butler MM; Bowlin TL; Lee RB; Lee RE; Lenaerts AJ
    J Antimicrob Chemother; 2017 Mar; 72(3):770-777. PubMed ID: 27999020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis.
    Gonzalez-Juarrero M; Lukka PB; Wagh S; Walz A; Arab J; Pearce C; Ali Z; Ryman JT; Parmar K; Temrikar Z; Munoz-Gutierrez J; Robertson GT; Liu J; Lenaerts AJ; Daley C; Lee RE; Braunstein M; Hickey AJ; Meibohm B
    ACS Infect Dis; 2021 Oct; 7(10):2850-2863. PubMed ID: 34546724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis.
    Lanoix JP; Lenaerts AJ; Nuermberger EL
    Dis Model Mech; 2015 Jun; 8(6):603-10. PubMed ID: 26035868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
    Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.
    Lanoix JP; Betoudji F; Nuermberger E
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1091-6. PubMed ID: 26643352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.
    Ahmad Z; Tyagi S; Minkowsk A; Almeida D; Nuermberger EL; Peck KM; Welch JT; Baughn AS; Jacobs WR; Grosset JH
    Indian J Med Res; 2012 Nov; 136(5):808-14. PubMed ID: 23287128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
    de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
    Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.
    De Groote MA; Gilliland JC; Wells CL; Brooks EJ; Woolhiser LK; Gruppo V; Peloquin CA; Orme IM; Lenaerts AJ
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1237-47. PubMed ID: 21135176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.
    Liu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Harrison T; Davies G; Coates A; Hu Y
    J Antimicrob Chemother; 2018 Mar; 73(3):724-731. PubMed ID: 29244108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis.
    Byrne ST; Denkin SM; Zhang Y
    J Antimicrob Chemother; 2007 Feb; 59(2):313-6. PubMed ID: 17185297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis.
    Bauman AA; Sarathy JP; Kaya F; Massoudi LM; Scherman MS; Hastings C; Liu J; Xie M; Brooks EJ; Ramey ME; Jones IL; Benedict ND; Maclaughlin MR; Miller-Dawson JA; Waidyarachchi SL; Butler MM; Bowlin TL; Zimmerman MD; Lenaerts AJ; Meibohm B; Gonzalez-Juarrero M; Lyons MA; Dartois V; Lee RE; Robertson GT
    Antimicrob Agents Chemother; 2024 Nov; 68(11):e0071624. PubMed ID: 39345140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis.
    Bauman AA; Sarathy JP; Kaya F; Massoudi LM; Scherman MS; Hastings C; Liu J; Xie M; Brooks EJ; Ramey ME; Jones IL; Benedict ND; Maclaughlin MR; Miller-Dawson JA; Waidyarachchi SL; Butler MM; Bowlin TL; Zimmerman MD; Lenaerts AJ; Meibohm B; Gonzalez-Juarrero M; Lyons MA; Dartois V; Lee RE; Robertson GT
    bioRxiv; 2024 May; ():. PubMed ID: 38798577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.
    Xu J; Li SY; Almeida DV; Tasneen R; Barnes-Boyle K; Converse PJ; Upton AM; Mdluli K; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30833432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delamanid Kills Dormant Mycobacteria
    Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fighting tuberculosis by drugs targeting nonreplicating
    Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
    Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
    Tasneen R; Garcia A; Converse PJ; Zimmerman MD; Dartois V; Kurbatova E; Vernon AA; Carr W; Stout JE; Dooley KE; Nuermberger EL
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0239821. PubMed ID: 35315690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.
    Ahmad Z; Nuermberger EL; Tasneen R; Pinn ML; Williams KN; Peloquin CA; Grosset JH; Karakousis PC
    J Antimicrob Chemother; 2010 Apr; 65(4):729-34. PubMed ID: 20123722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
    Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin adjunctive therapy shortens the duration of TB treatment in mice.
    Dutta NK; Bruiners N; Pinn ML; Zimmerman MD; Prideaux B; Dartois V; Gennaro ML; Karakousis PC
    J Antimicrob Chemother; 2016 Jun; 71(6):1570-7. PubMed ID: 26903278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.